Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
62 hedge funds and large institutions have $101M invested in Taro Pharmaceutical Industries Ltd. in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 7 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
0% more funds holding
Funds holding: 62 → 62 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
4% less capital invested
Capital invested by funds: $105M → $101M (-$4.33M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$1.42M |
| 2 |
Millennium Management
New York
|
+$931K |
| 3 |
EP
Eversept Partners
New York
|
+$578K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$410K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$399K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.1M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.75M |
| 3 |
BlackRock
New York
|
-$399K |
| 4 |
Renaissance Technologies
New York
|
-$362K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$286K |
TARO Hedge Fund Activity: Q1 2023 in Review
62 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q1 2023, worth a combined $101M — down 4.1% from $105M a quarter earlier.
Fund positioning in TARO was balanced in Q1 2023: 7 funds opened new positions, 7 closed out, 22 added to existing stakes and 19 trimmed.
The largest buyer was Brandes Investment Partners, adding an estimated $1.42M. The largest seller was Ameriprise, cutting an estimated $2.1M.
- 62 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $101M of Taro Pharmaceutical Industries Ltd. stock for Q1 2023, down 4.1% quarter-over-quarter.
- 7 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q1 2023 and 7 closed out, a net change of 0 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q1 2023 was Brandes Investment Partners, an estimated $1.42M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q1 2023 was Ameriprise, an estimated $2.1M sold.
Based on aggregated 13F filings for Q1 2023.